TT-036 for the treatment of scleroderma-associated pulmonary fibrosis
Ended Project Grant Awarded Last action
- Award ID
- R41HL176277
- Recipient
-
Thendor Therapeutics Inc. UEI Q9D5S4TLQG21
- Awarding agency
-
National Heart Lung and Blood Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $389,754
Award facts
- Assistance listing
- 93.837 Cardiovascular Diseases Research
- Completion date
- Place of performance
- South Carolina, USA
Award details come from USAspending.gov.
Description
- Abstract
- Fibroproliferative illnesses leading to organ fibrosis and failure are responsible for approximately 45% of deaths in developed countries. Whether idiopathic, triggered by environmental factors, infections, or genetics, organ fibrosis results in significant morbidity and mortality. Organ fibrosis is responsible for health care costs exceeding $10 billion/year. IT is estimated that the number of deaths due to fibrosis is double the number of deaths due to cancer, and that organ fibrosis results in significant physical, emotional, and financial burdens. Specifically, lung fibrosis can be idiopathic, associated with connective tissue diseases such as systemic sclerosis (SSC), or triggered by environmental and occupational exposures such as radiotherapy. Lung involvement is currently the leading cause of death of patients with SSC. There are currently no effective therapies to treat existing lung fibrosis as recently approved drugs merely reduce disease progression and result in significant side effects. Thus, the only curative option for patients is organ transplantation, which is impossible at the scale needed. We have identified a peptide derived from collagen XVIII which exerts anti-fibrotic effects in murine and human pre- clinical models of lung fibrosis. The beneficial effects include reducing fibrosis in lung tissues of patients with pulmonary fibrosis who underwent lung transplantation and thus have end-stage severe fibrosis, an effect not seen with other drugs that are approved or being evaluated for these illnesses. We propose to assess the therapeutic potential of the peptide in vivo in a murine model of lung fibrosis. We also propose to identify the minimal effective dose and optimal dosing frequency and conduct pilot toxicity, pharmacokinetic, and biodistribution analyses. Successful completion of this project will support our long-term goal of translating our findings to the clinic and providing patients with pulmonary fibrosis with an effective therapy. Identifying a peptide effective at reducing fibrosis represents a critical unmet need. Our approach is also likely to have broad impact and relevance for fibrosis in different organs.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Amendment | $0 | |
| Original award | $389,754 |
Quick answers
Who received award R41HL176277?
R41HL176277 was awarded to Thendor Therapeutics Inc. by National Heart Lung and Blood Institute (National Institutes of Health) on September 5, 2024.
How much is award R41HL176277 worth?
$389,754 has been obligated on R41HL176277.
On GovTribe
See this award's full record
- Every transaction and subaward
- The recipient's other awards and teaming partners
- Similar grant awards
- Ask GovTribe AI about this award